Insulin-like growth factor-I receptor signaling and resistance in breast cancer

References

• Adams TE, Epa VC, Garrett TPJ, Ward CW. Structure and function of the Type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 57, 1050–1093 (2000).
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. The IGF system and breast cancer. Endocr. Relat. Cancer 8, 197–209 (2001).
   PubMed Web of Science ®Google Scholar
• Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr. Rev. 22, 53–74 (2001).
   PubMed Web of Science ®Google Scholar
• Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen. Comp. Endocrinol. 142(1–2), 44–52 (2005).
   PubMed Web of Science ®Google Scholar
• Ricort JM. Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm. IGF Res. 4, 277–86 (2004).
   Google Scholar
• Oates AJ, Schumaker LM, Jenkins SB et al. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res. Treat. 47, 269–281 (1998).
   PubMed Web of Science ®Google Scholar
• White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog. Horm. Res. 53, 119–138 (1998).
   PubMedGoogle Scholar
• Le Roith. Regulation of proliferation and apoptosis by the insulin-like growth Factor I receptor. Growth Horm. IGF Res. 10(Suppl. A), S12–S13 (2000).
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Kadowaki T, Tobe K et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372(6502), 182–186 (1994).
   PubMed Web of Science ®Google Scholar
• Qu BH, Karas M, Koval A, Le Roith D. Insulin receptor substrate-4 enhances insulin-like growth factor-I-induced cell proliferation. J. Biol. Chem. 274(44), 31179–31184 (1999).
   PubMed Web of Science ®Google Scholar
• Dufourny B, Alblas J, van Teeffelen HA et al. Mitogenic signaling of insulin-like growth Factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J. Biol. Chem. 272(49), 31163–31171 (1997).
   PubMed Web of Science ®Google Scholar
• Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem. 273(16), 9994–10003 (1998).
   PubMed Web of Science ®Google Scholar
• Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res. 23(3), 385–394 (2004).
   PubMed Web of Science ®Google Scholar
• Bahr C, Groner B. The IGF-I receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 23(1), 1–14 (2005).
   PubMed Web of Science ®Google Scholar
• Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth Factor I-stimulated chemotaxis of human breast cancer cells. J. Biol. Chem. 271(5), 2443–2447 (1996).
   PubMed Web of Science ®Google Scholar
• Sachdev D, Hartnell JS, Lee AV, Zhang X, Yee D. A dominant negative Type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279(6), 5017–5024 (2003).
   PubMed Web of Science ®Google Scholar
• Long L, Navab R, Brodt P. Regulation of the Mr 72,000 Type IV collagenase by the Type I insulin-like growth factor receptor. Cancer Res. 58(15), 3243–3247 (1998).
   PubMed Web of Science ®Google Scholar
• Lee OH, Bae SK, Bae MH et al. Identification of angiogenic properties of insulin-like growth Factor II in in vitro angiogenesis models. Br. J. Cancer 82(2), 385–391 (2000).
   PubMed Web of Science ®Google Scholar
• Mercurio AM, Bachelder RE, Chung J et al. Integrin laminin receptors and breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 6(3), 299–309 (2001).
   PubMed Web of Science ®Google Scholar
• Koda M, Sulkowska M, Kanczuga-Koda L, Sulkowski S. Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases. J. Clin. Pathol. 58(6), 645–649 (2005).
   PubMed Web of Science ®Google Scholar
• Giles ED, Singh G. Role of insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis. Clin. Exp. Metastasis 20(6), 481–487 (2003).
   PubMed Web of Science ®Google Scholar
• Alessi DR. Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem. Soc. Trans. 29(Pt 2), 1–14 (2001).
   PubMedGoogle Scholar
• Peruzzi F, Prisco M, Dews M et al. Multiple signalling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell. Biol. 19(10), 7203–7215 (1999).
   PubMed Web of Science ®Google Scholar
• Heck S, Lezoualch F, Engert S, Behl C. Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor κB. J. Biol. Chem. 274(14), 9828–9835 (1999).
   PubMed Web of Science ®Google Scholar
• Kops GJ, Burgering BM. Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J. Anat. 197(Pt 4), 571–574 (2000).
   PubMed Web of Science ®Google Scholar
• O’Connor R, Fennelly C, Krause D. Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem. Soc. Trans. 28(2), 47–51 (2000).
   PubMed Web of Science ®Google Scholar
• Le Roith D, Helman L. The new kid on the block(ade) of the IGF-I receptor. Cancer Cell 5(3), 201–202 (2004).
   PubMed Web of Science ®Google Scholar
• Dunn SE, Ehrlich M, Sharp NJH et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58(15), 3353–3361 (1998).
   PubMed Web of Science ®Google Scholar
• Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res. Treat. 56(1), 1–10 (1999).
   PubMed Web of Science ®Google Scholar
• Ciftci K, Su J, Trovitch PB. Growth factors and chemotherapeutic modulation of breast cancer cells. J. Pharm. Pharmacol. 55(8), 1135–1141 (2003).
   PubMed Web of Science ®Google Scholar
• Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol. Rep. 8(2), 325–329 (2001).
   PubMed Web of Science ®Google Scholar
• Min Y, Adachi Y, Yamamoto H et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res. 63(19), 6432–6441 (2003).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5(3), 221–230 (2004).
   PubMed Web of Science ®Google Scholar
• Warshamana-Greene GS, Litz, J, Buchdunger E, Garcia-Echeverria C, Hofman F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res. 11(4), 1563–1571 (2005).
   PubMed Web of Science ®Google Scholar
• Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57(15), 3079–3083 (1997).
   PubMed Web of Science ®Google Scholar
• Macaulay VM, Salisbury, Bohula EA, Platford MP, Smorodinsky NI, Shiloh Y. Downregulation of the Type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene (30), 4029–4040 (2001).
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Carapancea M, Castro J et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett. 222(2), 173–181 (2005).
   PubMed Web of Science ®Google Scholar
• Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild type and mutant human prostate cancer. Cancer Gene Ther. 12(1), 90–100 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and endocrine resistance: observations with anti-estrogens and signal transduction inhibitors in combination. Clin. Cancer Res. 10(1 Pt 2), 346S–352S (2004).
   PubMed Web of Science ®Google Scholar
• Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 5, 107–115 (2000).
   PubMed Web of Science ®Google Scholar
• Hamelers IHL, Steenbergh PH Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer 10, 331–345 (2003).
   PubMed Web of Science ®Google Scholar
• Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl Acad. Sci. USA 101(7), 2076–2081 (2004).
   PubMed Web of Science ®Google Scholar
• Daly RJ, Harris WH, Wang DY, Darbre PD. Autocrine production of insulin-like growth Factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ. 2, 457–464 (1991).
   PubMedGoogle Scholar
• Surmacz E, Burgaud J L. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin. Cancer Res. 1, 1429–1436 (1995).
   PubMed Web of Science ®Google Scholar
• Abdul-Wahab K, Corcoran D, Perachiotti A, Darbre PD. Overexpression of insulin-like growth Factor II (IGFII) in ZR-75–1 human breast cancer cells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression. Cell Prolif. 32, 271–287 (1999).
   PubMed Web of Science ®Google Scholar
• van den Berg HW, Claffie D, Boylan M, McKillen J, Lynch M, McKibben B. Expression of receptors for epidermal growth factor and insulin-like growth Factor I by ZR-75–1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth Factor I receptor expression. Br. J. Cancer 73, 477–481 (1996).
   PubMed Web of Science ®Google Scholar
• Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF7 human breast cancer cells. J. Biol. Chem. 276, 40080–40086 (2001).
   PubMed Web of Science ®Google Scholar
• Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J. Biol. Chem. 278, 30458–30468 (2003).
   PubMed Web of Science ®Google Scholar
• Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth Factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 57, 2606–2610 (1997).
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer 29A, 2256–2264 (1993).
   PubMed Web of Science ®Google Scholar
• Parisot JP, Hu XF, DeLuise M, Zalcberg. Altered expression of the IGF-I receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer 79, 693–700 (1999).
   PubMed Web of Science ®Google Scholar
• Brockdorff BL, Heiberg I, Lykkesfeldt AE. Resistance to different anti-estrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Iα. Endocr. Relat. Cancer 10, 579–590 (2003).
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. IGF-IR signalling in tamoxifen-resistant breast cancer: A supporting role to the role to the epidermal growth factor receptor. Endocrinology 146(11), 4609–4618 (2005).
   PubMed Web of Science ®Google Scholar
• Maxwell P, van den Berg HW. Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett. 139, 121–127 (1999).
   PubMed Web of Science ®Google Scholar
• Knowlden J, Hutcheson IR, Jones HE et al. Elevated levels of EGFR/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in Tamoxifen resistant MCF-7 cells. Endocrinology 144(3), 1032–1044 (2003).
   PubMed Web of Science ®Google Scholar
• Coppola D, Ferber A, Miura M et al. A functional insulin-like growth Factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol. 14, 4588–4595 (1994).
   PubMed Web of Science ®Google Scholar
• Gilmore AP, Valentijn AJ, Wang P et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277, 27643–27650 (2002).
   PubMed Web of Science ®Google Scholar
• Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-I-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J. Biol. Chem. 275, 22583–22589 (2000).
   PubMed Web of Science ®Google Scholar
• Wang D, Pati S, Li W, Humphrey LE, Brattain MG, Howell GM. Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21, 2785–2796 (2002).
   PubMed Web of Science ®Google Scholar
• Gee JMW, Knowlden JM. Viewpoint: ADAM metalloproteases and EGFR signalling. Breast Cancer Res. 5, 223–224 (2003).
   PubMed Web of Science ®Google Scholar
• Balana ME, Labriola L, Salatino M et al. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and Type I insulin-like growth factor receptor in mammary tumour cells. Oncogene 20(1), 34–47 (2001).
   PubMed Web of Science ®Google Scholar
• Biscardi JS, Maa M-C, Tice DA, Cox ME, Leu T-H, Parsons SJ. C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr 1101 is associated with modulation of receptor function. J. Biol. Chem. 274(12), 8335–8343 (1999).
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93(24), 1852–1857 (2001).
   PubMed Web of Science ®Google Scholar
• Bartucci M, Morelli C, Mauro L, Ando' S, Surmacz E. Differential insulin-like growth Factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 61(18), 6747–6754 (2001).
   PubMed Web of Science ®Google Scholar
• Brunner N, Moser C, Clarke R, Cullen K. IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence. Breast Cancer Res. Treat. 22(1), 39–45 (1992).
   PubMed Web of Science ®Google Scholar
• Chernicky CL, Yi L, Tan H, Gan SU, Ilan J. Treatment of human breast cancer cells with antisense RNA to the Type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther. 7(3), 84–95 (2000).
   Google Scholar
• Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 22(1), 101–106 (1992).
   PubMed Web of Science ®Google Scholar
• Surmacz E. Function of the IGF-I receptor in breast cancer. Mammary Gland Biol. Neoplasia 5(1), 95–105 (2000).
   PubMed Web of Science ®Google Scholar
• Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J. Pathol. 183(4), 412–417 (1997).
   PubMed Web of Science ®Google Scholar
• Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL. Elevated insulin-like growth Factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 58(6), 159–164 (1998).
   PubMed Web of Science ®Google Scholar
• Pandini G, Vigneri R, Costantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signalling. Clin. Cancer Res. 5(7), 1935–1944 (1999).
   PubMed Web of Science ®Google Scholar
• Giani C, Campani D, Rasmussen A et al. Insulin-like growth Factor II (IGF-II) immunohistochemistry in breast cancer: relationship with the most important morphological and biochemical prognostic parameters. Int. J. Biol. Markers 17(2), 90–95 (2002).
   PubMed Web of Science ®Google Scholar
• Rocha RL, Hilsenbeck SG, Jackson JG et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 3(1), 103–109 (1997).
   PubMed Web of Science ®Google Scholar
• Gee JM, Robertson JF, Gutteridge E et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 12(Suppl. 1), S99–S111 (2005).
   PubMed Web of Science ®Google Scholar
• Schnarr B, Strunz K, Ohsam J, Benner A, Wacker J, Mayer D. Downregulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer 89(6), 506–513 (2000).
   PubMed Web of Science ®Google Scholar
• Toropainen EM, Lipponen PK, Syrjanen KJ. Expression of insulin-like growth Factor II in female breast cancer as related to established prognostic factors and long-term prognosis. Anticancer Res. 15(6B), 2669–2674 (1995).
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Peyrat JP, Beuscart R, De-maille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 50(21), 6931–6935 (1990).
   PubMed Web of Science ®Google Scholar
• Railo MJ, von Smitten K, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer 30A(3), 307–311 (1994).
   PubMed Web of Science ®Google Scholar
• Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in nodenegative breast cancer. Proc. Assoc. Am. Physicians 109, 565–571 (1997).
   PubMedGoogle Scholar
• Perez-Tenorio G, Stal O; Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86(4), 540–545 (2002).
   PubMed Web of Science ®Google Scholar
• Baselga J. Clinical trials of Herceptin (traztuzumab). Eur. J. Cancer 37(Suppl. 1), 18–23 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), S9–S15 (2001).
   PubMedGoogle Scholar
• Nicholson RI, Hutcheson IR, Hiscox SE et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of antigrowth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr. Relat. Cancer 12(Suppl. 1), S29–S36 (2005).
   Google Scholar
• Ross JS, Schenkein DP, Pietrusko R et al. Targeted therapies for cancer. Am. J. Clin. Pathol. 122, 598–609 (2004).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer 12(Suppl. 1), S135–S144 (2005).
   Web of Science ®Google Scholar
• Vidal L, Attard G, Kaye S, De Bono J. Reversing resistance to targeted therapy. J. Chemother. 16(Suppl. 4), 7–12 (2004).
   PubMed Web of Science ®Google Scholar
• Jones HE, Goddard L, Gee JMW et al. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 11, 1–22 (2004).
   PubMed Web of Science ®Google Scholar
• McClelland RA, Barrow D, Madden T et al. Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long-term culture in the presence of the pure anti-oestrogen FASLODEXTM. Endocrinology 142(7), 2776–2788 (2001).
   PubMed Web of Science ®Google Scholar
• Jones HE, Gee JMW, Taylor KM et al. Development of strategies for the use of antigrowth factor treatments. Endocr. Relat. Cancer 12(Suppl. 1), S173–S182 (2005).
   PubMed Web of Science ®Google Scholar
• Chakravati A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastome cells through continued activation of phosphoinositide 3-kinase signalling. Cancer Res. 62, 200–207 (2002).
   PubMed Web of Science ®Google Scholar
• Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20, 1913–1922 (2001).
   PubMed Web of Science ®Google Scholar
• Gullick WJ. The Type I growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer 8, 75–82 (2001).
   PubMed Web of Science ®Google Scholar
• Adams TE, McKern NM, Ward CW. Signalling by the Type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 22(2), 89–95 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed. Pharmacother. 57, 447–451 (2003).
   PubMed Web of Science ®Google Scholar
• Gutteridge E, Gee JM, Nicholson RI, Robertson JFR. Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer. Proc. Am. Soc. Clin. Oncol. 23, 38 (2004) (Abstract 648).
   Google Scholar
• Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signlling pathway in breast cancer cells. Biochem. Biophys. Res. Comm. 313, 709–715 (2004).
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin. Cancer Res. 11(2 Pt 2), S944–S950 (2005).
   PubMedGoogle Scholar
• Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today 10(15), 1041–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin like growth Factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63, 5073–5083 (2003).
   PubMed Web of Science ®Google Scholar
• Burtrum D, Zhu Z, Lu D et al. A fully human monoclonal antibody to the insulin-like growth Factor I receptor blocks ligand-dependent signalling and inhibits human tumor growth in vivo. Cancer Res. 63(24), 8912–8921 (2003).
   PubMed Web of Science ®Google Scholar
• Goetsch A, Gonzalez A, Leger O et al. recombinant humanized anti-insulin-like growth factor receptor Type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113(2), 316–328 (2005).
   PubMed Web of Science ®Google Scholar
• Ye JJ, Liang SJ, Guo N et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the Type I IGF receptor on breast tumor growth in vivo. Horm. Metab. Res. 35(11–12), 836–842 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C et al. Combination therapy enhances the inhibition of tumor growth with the fully human antitype 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11(5), 2063–2073 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5(3), 231–239 (2004).
   PubMed Web of Science ®Google Scholar
• Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64(1), 236–242 (2004).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Avnet S, Benini S et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer 101(1), 11–16 (2002).
   PubMed Web of Science ®Google Scholar
• Ingle JN, Suman VJ, Kardinal CG et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85(6), 1284–1292 (1999).
   PubMed Web of Science ®Google Scholar
• Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signalling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa™) in human breast cancer cells. Breast Cancer Res. 7(4), R570–R579 (2005).
   PubMed Web of Science ®Google Scholar
• Steinbach JP, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and Type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochem. Biophys. Res. Comm. 321(3), 524–530 (2004).
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280(20), 19665–19672 (2005).
   PubMed Web of Science ®Google Scholar
• Camirand A, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit. 8(12), BR521–BR526 (2002).
   PubMedGoogle Scholar
• Camirand A, Pollak M. Co-targeting IGF-IR and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br. J. Cancer 90(9), 1825–1829 (2004).
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 17, 73–89 (2003).
   PubMedGoogle Scholar
• Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm. Metab. Res. 35, 778–785 (2003).
   PubMed Web of Science ®Google Scholar
• Jones HE, Gee JMW, Barrow D, Wakeling AE, Guy S, Nicholson RI. De novo resistance to epidermal growth factor receptor blockade by gefitinib in colorectal cancer cells involves increased insulin receptor isoform A signalling. Eur. J. Cancer 2(8), 102 (2004) (Abstract 336).
   Google Scholar
• Frasca F, Pandini G, Scalia P et al. Insulin receptor isoform A, a newly recognized, high affinity insulin-like growth Factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19, 3278–3288 (1999).
   PubMed Web of Science ®Google Scholar
• Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth Factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 277(42), 39684–39695 (2002).
   PubMed Web of Science ®Google Scholar